Team Ashton

This project will develop and validate a series of ultrasensitive multiplex immunoassays to quantify protein targets in plasma and cerebrospinal fluid, enabling broad evaluation across the Parkinson’s disease research. Development will be carried out collaboratively across biomarker development groups, and where appropriate, novel antibody strategies will be deployed, with analytical performance established and cross-validated to ensure robustness and reproducibility. The resulting immunoassays will be benchmarked using well-characterized datasets to assess their biological relevance. Upon validation, the panels will be widely available—either as commercial research-use only kits with a track toward In Vitro Diagnostic development.